Liau Chi-Ting, Chou Wen-Chi, Wei Kuo-Chen, Chang Chen-Nen, Toh Cheng-Hong, Jung Shih-Ming
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Tao-Yuan, Taiwan.
Department of Neurosurgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Tao-Yuan, Taiwan.
Asia Pac J Clin Oncol. 2018 Apr;14(2):e8-e14. doi: 10.1111/ajco.12747. Epub 2017 Aug 9.
The goals of this study were to assess the activity and safety profile of bevacizumab in Taiwan Chinese patients with recurrent glioblastoma, to determine whether their response differed from that reported in other clinical trials, and to examine potential prognostic factors for survival.
We retrospectively assessed patients who received bevacizumab for recurrent glioblastoma between 2012 and 2015. Twelve predefined variables and the outcomes of our cohort were analyzed.
In total, 76 patients with recurrent glioblastoma were analyzed. The overall response rate was 59.2%, including 19 patients (25.0%) with complete response and 26 patients (34.2%) with partial response. The median progression-free survival and overall survival were 5.2 months (95% confidence interval [CI], 4.6-5.8 months) and 7.8 months (95% CI, 5.8-9.8 months), respectively. Multivariate analysis identified sex and grade 3 posttreatment hypertension (systolic ≥ 160 mmHg or diastolic ≥ 100 mmHg) as the only independent predictive factors for progression-free survival and overall survival. Eastern Cooperative Oncology Group performance status was also found to be independently predictive of improved overall survival.
We showed good responses using bevacizumab and the progression-free survival and overall survival were comparable with those previously reported. The adverse events of bevacizumab in our study were generally acceptable and manageable. Female sex, good performance status, and grade 3 posttreatment hypertension were suggested to be associated with survival benefits.
本研究的目的是评估贝伐单抗在台湾胶质母细胞瘤复发患者中的活性和安全性，确定他们的反应是否与其他临床试验报告的不同，并研究生存的潜在预后因素。
我们回顾性评估了2012年至2015年间接受贝伐单抗治疗复发性胶质母细胞瘤的患者。分析了12个预定义变量和我们队列的结果。
总共分析了76例复发性胶质母细胞瘤患者。总缓解率为59.2%，包括19例（25.0%）完全缓解和26例（34.2%）部分缓解。无进展生存期和总生存期的中位数分别为5.2个月（95%置信区间[CI]，4.6 - 5.8个月）和7.8个月（95%CI，5.8 - 9.8个月）。多变量分析确定性别和3级治疗后高血压（收缩压≥160mmHg或舒张压≥100mmHg）是无进展生存期和总生存期的唯一独立预测因素。还发现东部肿瘤协作组体能状态是总生存期改善的独立预测因素。
我们使用贝伐单抗显示出良好的反应，无进展生存期和总生存期与先前报道的相当。我们研究中贝伐单抗的不良事件总体上是可接受和可管理的。女性、良好的体能状态和3级治疗后高血压被认为与生存获益相关。
